^
2ms
Trial completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
2ms
P1 data • Journal • Metastases
|
KDR (Kinase insert domain receptor)
|
cisplatin • etoposide IV • Recentin (cediranib)
3ms
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2025
Trial completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
Lynparza (olaparib) • Recentin (cediranib)
3ms
Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide. (PubMed, Acta Oncol)
Cediranib and thalidomide effectively reduced tumor size over time. The accessibility of Evans Blue outside the tumor core continuously decreased over time. The vascular density was significantly decreased after treatment while the proportion of normal vessels remained unchanged over time. In contrast to histological studies, DCE-MRI did not tackle any significant change in hemodynamic parameters, in the core or margins of the tumor, whatever the parameter used or the pharmacokinetic model used. While cediranib and thalidomide were effective in decreasing the tumor size, they were ineffective in transiently increasing the delivery of agents in the core and the margins of the tumor.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
thalidomide • Recentin (cediranib)
4ms
NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jun 2025
Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
4ms
Efficacy and safety of combination of poly-ADP-ribose polymerase inhibitor (PARPi) and chemotherapy compared with chemotherapy alone in treatment of recurrent ovarian carcinoma: a systematic review. (PubMed, Niger Med J)
Eight randomized controlled trials (RCTs) were included in the systematic review comprising 3,021 patients evaluated efficacy and safety of PARP inhibitors: Olaparib, niraparib and veliparib with combinations of bevacizumab, carboplatin, cisplatin, cediranib, cyclophosphamide and paclitaxel. Niraparib and veliparib were notably associated with grade 3 or higher anaemia, neutropenia, and thrombocytopenia, olaparib caused fatigue and gastrointestinal disturbances while bevacizumab and cediranib caused hypertension. This review suggested combined PARP inhibitor and chemotherapy significantly prolonged progression-free survival especially in patients with BRCA mutation compared to chemotherapy and the combined therapy is safe.
Review • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset)
|
Avastin (bevacizumab) • Lynparza (olaparib) • cisplatin • carboplatin • paclitaxel • Zejula (niraparib) • cyclophosphamide • veliparib (ABT-888) • Recentin (cediranib)
4ms
Trial completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
5ms
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. (PubMed, Clin Colorectal Cancer)
In patients with pMMR-CRC or PDAC, durvalumab + olaparib and durvalumab + cediranib showed limited antitumor activity. Different immune components of the TME were associated with treatment outcomes.
P2 data • Journal • Mismatch repair • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
6ms
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis. (PubMed, BMC Cancer)
PARPi-based therapy showed considerable efficacy for mCRPC patients with HRD in 2nd -line setting. However, patients should be treated accordingly based on their genetic background as well as the efficacy and safety of the selected regimen.
Clinical • Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
Lynparza (olaparib) • Rubraca (rucaparib) • abiraterone acetate • Recentin (cediranib)
6ms
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. (PubMed, Gynecol Oncol)
Cediranib/olaparib had clinical activity in both platinum-sensitive and -resistant ovarian cancer. Presence of HRR gene mutations was not associated with cediranib/olaparib activity in either setting.
P2 data • Journal • PARP Biomarker
|
HRD (Homologous Recombination Deficiency)
|
HRD
|
Lynparza (olaparib) • Recentin (cediranib)
8ms
NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
P2, N=122, Active, not recruiting, National Cancer Institute (NCI) | Terminated --> Active, not recruiting | Trial completion date: Jun 2022 --> Apr 2025
Enrollment closed • Trial completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
8ms
Trial completion date • Trial primary completion date • Metastases
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Truqap (capivasertib) • Recentin (cediranib)
8ms
Trial completion date • Combination therapy
|
cisplatin • pemetrexed • Recentin (cediranib)
8ms
Feature Engineering-Assisted Drug Repurposing on Disease-Drug Transcriptome Profiles in Gastric Cancer. (PubMed, Assay Drug Dev Technol)
Then, using the drug repurposing method with the Connectivity Map CLUE Query tools, potential drugs such as Forskolin, Gestrinone, Cediranib, Apicidine, and Everolimus, which showed a highly negative correlation with the expression levels of the selected genes, were identified. This study provides a method to develop new approaches to diagnosing and treating gastric cancer by comparing the transcriptome profiles of patients gastric cancer and performing a feature engineering-assisted drug repurposing analysis based on cancer data.
Journal
|
ETV3 (ETS Variant Transcription Factor 3)
|
everolimus • Recentin (cediranib)
8ms
NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
P2, N=122, Terminated, National Cancer Institute (NCI) | Active, not recruiting --> Terminated; Inadequate accrual rate
Trial termination • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
8ms
Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D. (PubMed, Int J Mol Sci)
We have previously documented that vitamin D and its low-calcaemic analogues enhance the anticancer activity of drugs including a classic chemotherapeutic-dacarbazine-and an antiangiogenic VEGFRs inhibitor-cediranib. In this study, we explored the response of A375 and RPMI7951 melanoma lines to CPL304110 (CPL110), a novel selective inhibitor of fibroblast growth factor receptors (FGFRs), and compared its efficacy with that of AZD4547, the first-generation FGFRs selective inhibitor...Interestingly, 1,25(OH)2D3 and CPL304110 co-treatment resulted in activation of the ERK1/2 pathway in A375 cells. Our results strongly suggested possible crosstalk between vitamin D-activated pathways and activity of FGFR inhibitors, which should be considered in further clinical studies.
Preclinical • Journal
|
FGFR (Fibroblast Growth Factor Receptor)
|
fexagratinib (ABSK091) • dacarbazine • Recentin (cediranib) • CPL304110
8ms
DAPPER: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P2, N=90, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
Trial completion date • Trial primary completion date • IO biomarker • Pan tumor • Metastases
|
HRD (Homologous Recombination Deficiency) • CD4 (CD4 Molecule)
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
9ms
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov)
P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
Recentin (cediranib)
9ms
Trial completion date
|
CASP3 (Caspase 3)
|
Koselugo (selumetinib) • Recentin (cediranib)
9ms
Trial completion date
|
BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
9ms
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. (PubMed, J Exp Clin Cancer Res)
These findings provide a preclinical framework supporting the potential of dual targeting HER2 and VEGFR as a promising therapeutic strategy to improve outcomes in patients with OC.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
Recentin (cediranib)
9ms
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway. (PubMed, Front Oncol)
Here, we demonstrated that anti-angiogenic agents, bevacizumab and cediranib, increased the sensitivity of olaparib in HRP EOC cells by suppressing HR activity. In addition, CRY1 inhibition also sensitized EOC cells to olaparib. These data suggested that anti-angiogenic agents and CRY1 inhibitors will be the promising candidate in the combination therapy with PARP inhibitors in HR-proficient EOC.
Journal • PARP Biomarker
|
RAD51 (RAD51 Homolog A) • CRY1, Cryptochrome Circadian Regulator 1,
|
CRY1 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Recentin (cediranib)
9ms
Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
10ms
Cediranib enhances the transcription of MHC-I by upregulating IRF-1. (PubMed, Biochem Pharmacol)
In vivo study, we further confirmed that cediranib increased MHC-I expression, enhanced CD8 T cell infiltration, and improved the efficacy of anti-PD-L1 therapy. Collectively, our study demonstrated that cediranib could elevate MHC-I expression and enhance responsiveness to immune therapy, thereby providing a theoretical foundation for its potential clinical trials in combination with immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IRF1 (Interferon Regulatory Factor 1)
|
CD8 expression • IRF1 expression
|
Recentin (cediranib)
10ms
OCTOVA: Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=139, Completed, University of Oxford | Active, not recruiting --> Completed
Trial completion
|
Lynparza (olaparib) • paclitaxel • Recentin (cediranib)
10ms
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. (PubMed, Br J Cancer)
OCTOVA demonstrated the activity of O + C in women with recurrent disease, offering a potential non-chemotherapy option.
P2 data • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Lynparza (olaparib) • paclitaxel • Recentin (cediranib)
11ms
Trial completion date • Metastases
|
Recentin (cediranib) • rifampicin
11ms
NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
P2, N=149, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2023
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
12ms
SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov)
P1/2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2
Phase classification • Combination therapy
|
cisplatin • pemetrexed • Recentin (cediranib)
12ms
Ex Vivo Drug Sensitivity Evaluation of a ZMYM2: : FGFR1 Fusion-Positive 8p11 Myeloproliferative Syndrome (EMS) Leukemia (ASH 2023)
Bortezomib and Axitinib exhibited high efficacy on the patient's sample...Other FGFR inhibitors, including Olverematinib, AZD4547, Axitinib, Cediranib, Dovitinib, and Lenvatinib, also demonstrated exquisite sensitivity. Despite extensive screening, no other single agents or drug combinations exhibited increased effectiveness in the ZMYM2: : FGFR1 transformed BaF3 cells except for Trametinib, a MEK inhibitor, and the combination of Belvarafenib (RAF inhibitor) and Gilteritinib (FLT3 inhibitor)... Ex vivo drug sensitivity assays demonstrated the highly selective efficacy of FGFR inhibitors in ZMYM2: : FGFR1 fusion-positive leukemia cells and a fusion-expressing BaF3 cell line. Mutations in the FGFR1 kinase domain (ZMYM2: : FGFR1 F1171L) could contribute to Ponatinib insensitivity. These ex vivo drug screening results provide further support for ongoing clinical trials which are investigating the use of single agent Pemigatinib and other FGFR1 inhibitors for the treatment of patients with FGFR1-fusion positive leukemias.
Preclinical
|
FLT3 (Fms-related tyrosine kinase 3) • FGFR1 (Fibroblast growth factor receptor 1) • RUNX1 (RUNX Family Transcription Factor 1)
|
RUNX1 mutation • FGFR fusion • FGFR1 fusion • FGFR1 expression • FGFR1 rearrangement
|
Mekinist (trametinib) • Iclusig (ponatinib) • Lenvima (lenvatinib) • bortezomib • Xospata (gilteritinib) • Pemazyre (pemigatinib) • Inlyta (axitinib) • fexagratinib (ABSK091) • belvarafenib (RG6185) • Recentin (cediranib) • dovitinib (TKI258)
12ms
Harnessing the Effects of Hypoxia-like Inhibition on Homology-directed DNA Repair. (PubMed, Semin Cancer Biol)
Preclinical results and Phase II and III clinical trial data support the mechanistic rationale for the efficacy of these agents in combination. Future investigations should explore the effectiveness of cediranib and other anti-angiogenic agents with a PARP inhibitor to elicit an antitumor response and sensitize cancers to immunotherapy.
Review • Journal • Tumor mutational burden • PARP Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden)
|
Recentin (cediranib)
12ms
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov)
P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Nov 2023
Trial completion date • Trial primary completion date • Metastases
|
sunitinib • Recentin (cediranib)
1year
NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
P2, N=164, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2024 --> Dec 2023
Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
1year
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
P2, N=72, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Aug 2024
Trial completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
Lynparza (olaparib) • Recentin (cediranib)
1year
NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
P2, N=149, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Nov 2024
Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
1year
Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045. (PubMed, Int J Cancer)
Based on comprehensive biomarker profiling, including immunohistochemistry, whole-exome and RNA sequencing and whole blood-based analyses, we identified biomarkers that could help inform which of the two combination strategies is appropriate given a patient's biomarker status. Our findings have the potential to improve treatment outcome for patients with ovarian cancer in the PARP inhibitor era.
P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset)
|
PD-L1 expression • BRCA mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
1year
Trial completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
over1year
Recent advancements and theranostics strategies in glioblastoma therapy. (PubMed, Biomed Mater)
Approaches utilized for targeted drug delivery to the GBM were also discussed.  This article also describes the recent in vivo, in vitro and ex vivo advances using innovative theranostic approaches.
Journal
|
Recentin (cediranib)
over1year
Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial. (PubMed, Clin Cancer Res)
Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some LMS patients. Baseline M1-macrophage and B-cell activity may identify LMS patients with favorable outcomes on immunotherapy and should be further evaluated.
Journal • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
over1year
Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023) (ESMO 2023)
Treatments were randomly assigned 1:2:2:2 to SOC (weekly paclitaxel, topotecan or liposomal doxorubicin), DOC, DC or OC. Conclusions None of the experimental arms improved PFS compared with SOC. SOC was active in this heavily pretreated population.
Clinical • P2 data • Combination therapy • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • topotecan • Recentin (cediranib)
over1year
A multicenter open-label randomized phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. (PubMed, Ann Oncol)
Single-agent therapy with cediranib showed promising efficacy in RAI-refractory DTC similar to other VEGFR-targeted TKIs, while the addition of lenalidomide did not result in clinically meaningful improvements in outcomes.
P2 data • Journal
|
lenalidomide • Recentin (cediranib)
over1year
COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P2/3, N=562, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)